Capital Group Investment Management PTE. LTD. Sells 4,015 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Capital Group Investment Management PTE. LTD. decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 31.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,666 shares of the biopharmaceutical company's stock after selling 4,015 shares during the period. Capital Group Investment Management PTE. LTD.'s holdings in Gilead Sciences were worth $800,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the company. Bridgewater Associates LP lifted its holdings in Gilead Sciences by 122.7% in the fourth quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock valued at $42,577,000 after acquiring an additional 253,994 shares during the period. McAdam LLC grew its stake in Gilead Sciences by 16.7% in the 4th quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company's stock valued at $2,344,000 after acquiring an additional 3,627 shares during the last quarter. Capital Investment Advisors LLC increased its position in Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company's stock worth $35,793,000 after purchasing an additional 9,791 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in Gilead Sciences by 3.9% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company's stock valued at $13,132,000 after purchasing an additional 5,382 shares in the last quarter. Finally, Global Financial Private Client LLC raised its position in shares of Gilead Sciences by 1,222.0% in the fourth quarter. Global Financial Private Client LLC now owns 6,068 shares of the biopharmaceutical company's stock valued at $561,000 after buying an additional 5,609 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total value of $260,225.00. Following the completion of the sale, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $17,597,559.49. The trade was a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 302,785 shares of company stock worth $30,540,875 in the last 90 days. Corporate insiders own 0.27% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on GILD. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Oppenheimer increased their target price on Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a research note on Tuesday, March 4th. Piper Sandler upped their target price on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a report on Tuesday. They issued an "overweight" rating and a $125.00 price target on the stock. Finally, Royal Bank of Canada boosted their price objective on Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a report on Wednesday, February 12th. Ten analysts have rated the stock with a hold rating, sixteen have given a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and an average price target of $106.92.

Gilead Sciences Trading Up 1.3 %

Shares of Gilead Sciences stock traded up $1.36 during trading on Tuesday, hitting $105.69. 2,010,947 shares of the company were exchanged, compared to its average volume of 8,826,381. The firm has a market capitalization of $131.60 billion, a P/E ratio of 285.90, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. The firm's fifty day moving average price is $109.18 and its 200 day moving average price is $97.77. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.99%. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date was Friday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is currently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.